Dr. Kindler is an associate editor of Lung Cancer and has published numerous journal articles, review articles, book chapters, and abstracts. A popular speaker, she has been invited to lecture at hundreds of scientific meetings around the world.
Dr. Kindler is the immediate past-president of the International Mesothelioma Interest Group. She is an active member of several committees and boards, including the Science Advisory Board of the Mesothelioma Foundation, the NCI Pancreatic Cancer Task Force and the Alliance for Clinical Trials in Oncology.
Repeatedly listed in Best Doctors in America, America’s Top Doctors for Cancer, and Top Doctors in Chicago. Dr. Kindler was recently awarded the Selikoff Lifetime Achievement Award by the Asbestos Disease Awareness Organization.
Specialties
Areas of Expertise
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- International Association for the Study of Lung Cancer
- Mesothelioma Applied Research Foundation
- Alliance for Clinical Trials in Oncology
- American Society of Clinical Oncology
- International Mesothelioma Interest Group
Practicing Since
- 1995
Languages Spoken
- English
Medical Education
- State University of New York College of Medicine
Residency
- University of California Los Angeles Health; Montefiore Medical Center
Fellowship
- Memorial Sloan Kettering Cancer Center
News & Research
View Published Papers- Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
- A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
- A Study of SGN-CD228A in Advanced Solid Tumors
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
- Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Olaparib in Patients With HRD Malignant Mesothelioma
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
- Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
- S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Pembrolizumab in Treating Patients With Malignant Mesothelioma
- Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
- A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient